Genelux Corp (GNLX) Stock Price & Analysis
Genelux Corp (GNLX) rose 4.10% to USD 2.54 as of September 9, 2026 at 12:47 UTC, according to Nexqual real-time market data.
GNLX last closed at USD 2.44; the session ranged USD 2.39–2.54 on volume of 408,290 shares. Market capitalization is $114.92M, with a 52-week range of USD 2.29–8.54 (NCM). Source: Nexqual, September 9, 2026 at 12:47 UTC.
Key Statistics (as of September 9, 2026 at 12:47 UTC)
| Price | USD 2.54 |
|---|---|
| Change | ▲ 4.10% (up) |
| Previous Close | USD 2.44 |
| Open | USD 2.5 |
| Day Range | USD 2.39 – 2.54 |
| 52-Week Range | USD 2.29 – 8.54 |
| Volume | 408,290 shares |
| Market Cap | $114.92M |
| Exchange | NCM |
Technical Analysis (GNLX)
Nexqual's technical model rates GNLX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of September 9, 2026 at 12:47 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.46 (neutral) |
| vs SMA50 | Below (USD 2.8) |
| MACD | -0.07 (negative) |
Analyst Ratings (GNLX)
Wall Street analysts rate GNLX "Strong Buy" based on 5 analysts, with a mean price target of USD 19 (range USD 12–31), per Nexqual as of September 9, 2026 at 12:47 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 19 |
| High Target | USD 31 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (GNLX)
| EPS Estimate | USD -0.19 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.21 vs est -0.2 ▼ miss |
| 2026-03-31 | USD -0.2 vs est -0.2 ▲ beat |
| 2025-12-31 | USD -0.24 vs est -0.22 ▼ miss |
| 2025-09-30 | USD -0.21 vs est -0.21 ▲ beat |
Source: Nexqual, September 9, 2026 at 12:47 UTC.
Financials & Fundamentals (GNLX)
| Total Revenue | $8,000 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -455275.00% |
| Profit Margin | +0.00% |
| ROE | -177.93% |
| Debt / Equity | 15.02 |
| Current Ratio | 2.39 |
| Total Cash | $18.67M |
| Total Debt | $2.42M |
| Free Cash Flow | $-15.25M |
Source: Nexqual, September 9, 2026 at 12:47 UTC.
Financial Health Score (GNLX)
Nexqual rates Genelux Corp's overall financial health "Weak" across five dimensions, as of September 9, 2026 at 12:47 UTC.
| Growth | Mixed — Revenue +0.0% YoY (annual), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $19M cash vs $2M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$15M, burning cash |
| Efficiency | Critical — ROE -178%, ROA -77.9% |
Ownership (GNLX)
| Insider Ownership | +12.87% |
|---|---|
| Institutional Ownership | +31.01% |
| Shares Outstanding | 45.25M |
| Float | 36.44M |
| Short % of Float | +8.01% |
Source: Nexqual, September 9, 2026 at 12:47 UTC.
Leadership (GNLX)
Genelux Corp is led by Thomas D. Zindrick (age 65), Chairman, CEO & President, per Nexqual as of September 9, 2026 at 12:47 UTC.
| Chairman, CEO & President | Thomas D. Zindrick (age 65) |
|---|---|
| CFO and Principal Financial & Accounting Officer | Matthew Pulisic (age 41) |
| Chief Scientific Officer | Yong Yu (age 53) |
Major Backers & Investors (GNLX)
Notable institutional backers of Genelux Corp include Woodward Diversified Capital, LLC, Bleichroeder LP, CM Management, LLC, according to Nexqual as of September 9, 2026 at 12:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Woodward Diversified Capital, LLC | 5% |
| Bleichroeder LP | 3.05% |
| CM Management, LLC | 0.88% |
| Fidelity | 0.8% |
| Bank of America Corporation | 0.73% |
| FLPutnam Investment Management Company | 0.51% |
| Global Retirement Partners, LLC | 0.5% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.94% |
| BlackRock | 1.28% |
| Geode Capital | 0.97% |
Source: Nexqual, September 9, 2026 at 12:47 UTC.
From Genelux Corp's Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
- Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
- It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates.
- The company has a licensing agreement with Newsoara BioPharma Co.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SGMT | Sagimet Biosciences Inc. - Seri | USD 10.71 | ▼ 1.92% |
| AZTR | Azitra Inc | USD 0.17 | ▼ 4.44% |
| SRZN | Surrozen, Inc. | USD 20.68 | ▼ 8.25% |
| EUDA | Euda Health Holdings Limited | USD 13.44 | ▼ 6.67% |
| INAB | IN8bio, Inc. | USD 1.14 | ▼ 1.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 12:47 UTC. This page is informational and not investment advice.